INTRODUCTION
Adrenal tumors are found increasingly more commonly because of the number of imaging studies obtained in the general population [1] . A small fraction of these tumors are producing hormones. Endogenous overproduction of cortisol by the adrenal adenomas may cause Cushing syndrome, associated with significant morbidity [2] . Adrenal Cushing syndrome is often missed, given that some of the patients have a subclinical or even cyclical Cushing syndrome. Overt Cushing syndrome is diagnosed in patients with significant metabolic abnormalities, such as weight gain, diabetes mellitus, hypertension, osteoporosis and others.
Genetic mutations, causing cortisol-producing tumors have been suspected for years, but only few genetic defects had been discovered until recently. Patients with McCune-Albright syndrome have somatic mutations in Guanine Nucleotide Binding Protein, Alpha Stimulating (GNAS)1 in their adrenal glands causing cortisol overproduction due to a unique form of bilateral adrenocortical hyperplasia (BAH) or single adenomas. Cushing syndrome caused by primary pigmented nodular adrenocortical disease (PPNAD) is due to mutations in cyclic AMP (cAMP)-dependent protein kinase A (PKA) type 1 alpha regulatory subunit (PRKAR1A) [3] . Recently, mutations in the armadillo repeat containing 5 (ARMC5), a tumor-suppressor gene, were found to be the cause of primary macronodular adrenal hyperplasia, formerly known as adrenocorticotropic
CYCLIC AMP SIGNALING PATHWAY
The cAMP/PKA pathway is crucial for the function of the adrenal gland [13, 14] (Fig. 1) . Corticotropin (ACTH) binds to its G protein-coupled transmembrane receptor (MC2R), leading to the synthesis of cAMP by adenylate cyclase [15] . cAMP, acting as a secondary messenger, targets tetramer PKA. The latter is a cAMP-dependent serine-kinase, consisting of two regulatory (with PRKAR1A being the main one) and two inactive catalytic subunits. cAMP binds to the regulatory subunits, dissolves the tetramer, thus enabling catalytic subunits to phosphorylate a number of targets, and activate transcription of the genes.
The role of the cAMP pathway in adrenal tumors associated with Cushing syndrome has been repeatedly shown. For example, inactivating mutations in PRKAR1A in patients with PPNAD lead to inactivation of R1a, which allows Ca to be uninhibited, resulting in PKA activation [16] .
THE PRKAR1A GENE, CARNEY COMPLEX, AND PRIMARY PIGMENTED NODULAR ADRENOCORTICAL DISEASE
Carney complex is a multiple endocrine neoplasia syndrome, inherited in an autosomal dominant pattern [17, 18] . Patients have PPNAD, as well as other endocrine neoplasms, such as pituitary adenoma and/or hyperplasia, thyroid and gonadal tumors. It is also associated with many nonendocrine lesions, such as spotty skin pigmentation (also known as 'lentiginosis'), myxomas and schwannomas [17, 19] . PPNAD, which causes an often indolent form of adrenal Cushing syndrome, is the most common endocrine manifestation of Carney complex. Most of the affected patients present as children or young adults. Patients have a rather unique 'paradoxical' rise of cortisol after the high-dose dexamethasone part of the Liddle's test [18, 20] .
There are two genetic loci (17q22-24 and 2p16), which are associated with this complex. Mutations in the PRKAR1A gene were first recognized in families with linkage to the 17q22-24 locus [21] . Approximately two-thirds of the patients affected by Carney complex have PRKAR1A mutations, in which no gene has been identified at the 2p16 locus to date [22] . PRKAR1A is likely to be a tumor suppressor gene, as the allelic loss of the wild-type allele is often seen in patients with Carney complex [3, 21] . To date more than 126 PRKAR1A mutations have been described. A publicly available database is available online, and continuously updated by our team (http://prkar1a.-nichd.nih.gov/hmdb/mutations.html). Most of these mutations encompass small deletions and single base substitutions, or open reading frame rearrangements, with a few large deletions reported [23] . An association between Carney complex and adrenal cancer was recently described in patients with PRKAR1A mutations [24, 25] . Other cancerous associations, such as hepatocellular carcinoma [26] and pancreatic malignancies have been reported [27] .
PRKACA DEFECTS AND CUSHING SYNDROME
Recently, Beuschlein et al. [28 && ] identified somatic activating mutations of the main catalytic subunit of PKA, PRKACA, in unilateral cortisol-producing adrenal tumors, causing overt Cushing syndrome; this discovery was confirmed by others [ 
&& ]. These groups performed whole-exome DNA sequencing of the available tumors and leukocyte DNA, and identified a recurring hotspot point PRKACA mutation (c.617A > C, also known as c.617T > G), resulting in arginine substitution of amino acid 206 (Leu206Arg).
Beuschlein et al. [28 && ] studied 139 patients with adrenal adenomas, adrenocortical carcinomas and ACTH-independent primary adrenal hyperplasias. These patients were screened for PDE8B, PDE11A and PRKAR1A mutations and were found to be negative. The researchers identified mutations in PRKACA in eight of the 10 originally screened unilateral cortisol-producing adenomas, with a majority (seven patients) having the c.617A > C, p.Leu206Arg mutation, whereas one had the insertion located at c.595_596CAC, Leu199_Cy-s200insTrp. The p.Leu206Arg mutation is located in a highly conservative core of the interaction
KEY POINTS
Somatic mutations of the main catalytic subunit of PKA, a serine-threonine kinase, PRKACA, may cause cortisolproducing adenomas and ACTH-independent Cushing syndrome.
Germline duplications of the PRKACA may result in bilateral adrenal hyperplasia.
Patients with PRKACA defects may have smaller tumors and more severe forms of Cushing syndrome.
The cAMP/PKA pathway is a potential target for molecularly designed therapies of Cushing syndrome. (a) Adrenocorticotropic hormone(ACTH) binds to its 7-transmembrane G-protein coupled receptor (GPCR), which activates Gsa protein and stimulates adenylate cyclase to generate cAMP (from ATP). PKA is a tetrameric enzyme, composed by two regulatory (R) and two catalytic (C) subunits, and is activated by an increase of the intracellular cAMP concentration, cAMP molecules bind to the R subunits which then set free the C subunits, resulting in phosphorylation of transcription factor cAMP response element binding protein (CREB) and other target molecules. Phosphodiesterases (PDEs), like PDE11A and PDE8B, bind cAMP and decrease its levels. (b). Increased PKA activity in the setting of somatic PRKACA mutations in patients with cortisol-producing adenomas is due to the lack of the mutant PRKACA's binding to the R subunits or due to excess C subunits caused by copy number gain of the gene coding for it.
PKA and cortisol-producing adrenal tumors Zilbermint and Stratakis between the regulatory (RIIb) and catalytic subunits of PKA. Importantly, these investigators described the clinical phenotype of these patients: 37% of the studied cohort had overt Cushing syndrome due to a unilateral cortisol-producing adenoma with a PRKACA mutation. These patients had a higher index of disease severity, as shown by increased urinary free cortisol and late-night serum cortisol levels. These findings were correlated with expression levels of the steroidogenic enzymes that were higher in tissues with PRKACA mutations. Patients with germline copy number gain of the PRKACA locus on chromosome 19p had BAH. Shortly after the initial report, we described in detail the three pathologic phenotypes of BAH of the previously reported [28 && ] five patients with germline PRKACA copy number gain. Three patients had a disease that looked like PPNAD along with extranodular cortical atrophy and mild intracapsular and extracapsular extension of adrenocortical cells, whereas others had cortical hyperplasia and capsular and extracapsular micronodular cortical hyperplasia [34 && ]. The described hotspot mutations [28 && ] may interfere with the creation of a stable PKA molecule and render the mutant Ca subunits constitutively active [35] . Cao et al. [29 & ] performed whole-exome sequencing of 49 tumors and RNA sequencing of 44 tumors, including cortisol-producing adenomas, carcinomas and ACTH-independent macronodular adrenal hyperplasia. They identified an even higher rate of somatic PRKACA mutations, 69.2% (27 out of 39). They published a hotspot c.617T > G, resulting in Leu205Arg substitution. It should be noted that this is the same mutation that was reported by Beuschlein et al. [28 && ]; apparently, Cao et al. [29 & ] used a different amino acid numbering system, in which initiating methionine is counted as residue zero (and not one), thus reporting Leu205Arg vs. Leu206Arg [36] . Interestingly, they found no statistical significant differences in serum cortisol, plasma ACTH and urinary free cortisol levels, when compared with the patients without PRKACA mutations. The researchers performed functional studies (gain of function mutation in 293T cells), and found that overexpression of Leu205Arg mutants increases phosphorylation of PKA derivatives relative to the wild type [29 & ]. In particular, the PRKACA Leu205Arg mutation induced phosphorylation of the cAMP response element binding protein, confirming the hypothesis that Leu205Arg mutation may enhance PKA activity [ ] investigated 149 frozen tumor samples from nine European medical centers, paired with leucocyte DNA and patients' clinical and biochemical data, when available. Similarly to the previous investigators, they found mutations of exon 7 of PRKACA gene in 34% studied samples, associated with Cushing syndrome. In addition to previously described missense mutation c.617A > C (p.Leu206Arg) (18 out of 22 patients), they found two novel mutations in another four patients (c.600_601insGTG/p.Cys200_Gly201insVal and c.639C > G þ c.638_640insATTATCCTGAGG/p. Ser213Argþp.Leu212_Lys214insIle-Ile-Leu-Arg). No germline PRKACA mutations were identified. The authors found higher levels of serum cortisol after dexamethasone testing, and smaller size of cortisolproducing adenomas.
Recently, Nakajima et al. [33 & ] screened tumors of 13 patients in Japan, and found recurrent somatic mutations of the PRKACA gene, p.L206R (c.617T > G) in 23% of patients with overt Cushing syndrome.
THE PRKACB GENE AND CARNEY COMPLEX
We recently found that genomic amplification of the PRKACB locus may lead to Carney complex without any PRKAR1A mutations [37 & ]. Forlino et al. [37 & ] described a single case of a 19-year-old female patient presenting with acromegaly and lentigines, who also had myxomas, but no Cushing syndrome. This patient had somatic copy number gain of the chromosome 1p31.1 PRKACB locus, leading to an increase of the PKA catalytic subunit Cb expression and higher PKA activity in the patient's cells. A mouse model, carrying a transgene for human PRKACB, had an increase in growth hormone secretion [37 & ].
CONCLUSION
Somatic mutations in PRKACA may be a frequent cause of Cushing syndrome in patients with adrenal adenomas, whereas BAH may be caused by PRKAR1A or PRKACA defects. PRKACA mutations that lead to Cushing syndrome prevent the binding of the catalytic to the regulatory subunits, thus causing constitutive and cAMP-independent activation of PKA, and eventually, autonomous overproduction of cortisol. It is possible that larger tumors produce cortisol less efficiently, whereas smaller tumors may be more steroidogenic. This exciting discovery has been well covered in the scientific literature [ [45] reported increased PRKACA expression in trastuzumab-resistant breast cancer, suggesting that the cAMP/PKA pathway may be stimulated in some breast cancers. Fibrolamellar hepatocellular carcinoma was found to be due to a recurrent DnaJ homolog subfamily B member 1 (DNAJB1)-PRKACA chimeric transcript [46] . Parathyroid hormone receptor and parathyroid related protein may promote tumor invasion and proliferation in osteosarcoma, via enhanced PKA signaling [47] . Vitali et al. [48] showed that cAMP surges DNA synthesis and cyclin D1 expression in somatotropinomas, and abolishes in prolactinomas and nonfunctioning pituitary tumors.
The new genetics of Cushing syndrome may assist clinicians to provide appropriate counseling and in their decision-making regarding medical and/or surgical intervention. These findings may also lead to the development of individualized pharmacological treatment(s) for Cushing syndrome and other disease associated with PKA defects. 
